2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 2
1
Status
Recruiting
3
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
43
Tumor-Agnostic
8
Gastrointestinal
6
CNS
6
Lymphoid
4
Genitourinary
4
Sarcoma
3
Other hematologic neoplasm
3
Breast
3
Head & Neck
2
Gynecologic
2
Endocrine
2
Other solid neoplasm
1
Other
1
NET
1
Dermatologic
1
Conditions
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Neuroblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Carcinoma, Renal Cell
1
Interventions
Cytarabine
905
Cyclophosphamide
899
fludarabine
525
venetoclax
489
fludarabine phosphate
468
Azacitidine
460
Rituximab
431
Methotrexate
419
Etoposide
320
Filgrastim
299
Busulfan
296
Dexamethasone
286
Vincristine
285
Daunorubicin
283
Peripheral Blood Stem Cell Transplantation
258
Whole-Body Irradiation
243
Mycophenolic Acid
232
Decitabine
230
Granulocyte Colony-Stimulating Factor
227
Tacrolimus
220
Imatinib Mesylate
211
Idarubicin
205
Melphalan
202
Cyclosporine
182
Doxorubicin
177
Radiotherapy
169
Prednisone
164
Dasatinib
163
Mitoxantrone
161
Lenalidomide
160
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
alectinib
×
Other hematologic neoplasm
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT05159245
2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2
Recruiting
250 enrolled